Zomedica: The Pet Tech Play

Zomedica is building more than a product suite, it is creating an integrated veterinary ecosystem. Its diagnostics (TRUFORMA, TRUVIEW), therapeutics (PulseVet, Assisi), and monitoring solutions (VetGuardian) are designed to work together within a clinic’s workflow. This matters because veterinarians don’t operate in silos, they diagnose, treat, and monitor patients continuously. By embedding itself across this full journey, Zomedica increases its relevance per patient interaction. This ecosystem approach also strengthens customer retention. Once a clinic adopts multiple products, switching becomes more difficult due to training, workflow integration, and data continuity. Over time, this creates a “platform effect” where each additional product increases the value of the others. Importantly, very few competitors offer both diagnostics and therapeutics at this level of integration, giving Zomedica a differentiated position in a fragmented market.

The business model is increasingly shifting toward recurring revenue, which is critical for both valuation and predictability. While initial device placements generate upfront revenue, the real value lies in ongoing consumables, diagnostic cartridges, therapy components, and repeat usage of systems. Already, consumables account for roughly 70% of revenue and are growing faster than capital equipment sales. This dynamic creates a compounding effect. Each new device placement expands the installed base, which in turn drives future consumables usage. As adoption increases, revenue per clinic can grow without needing proportional increases in sales effort. Additionally, recurring revenue tends to carry higher margins and greater visibility, improving the overall quality of earnings. Over time, this shifts the perception of the company from a device manufacturer to a platform with annuity-like revenue characteristics.

One of the most compelling aspects of the Zomedica story is the relatively clear and achievable path to breakeven. Management has indicated that approximately $55m in annual revenue would deliver cash flow breakeven. With current revenue already exceeding $30m, the gap is meaningful but not extreme, especially considering the size of the addressable market. Crucially, this does not require dominant market share, just incremental penetration and improved utilisation of existing products. At the same time, the company has demonstrated strong cost discipline, reducing operating expenses and cash burn while maintaining growth. This combination of revenue expansion and cost control creates operating leverage, meaning each additional dollar of revenue contributes more significantly to profitability. For investors, this provides a tangible milestone that could act as a key inflection point in how the market values the business.

• New product launches gaining traction: Adoption of TRUVIEW AI and VetGuardian PLUS should increase revenue per clinic and validate demand for AI-driven diagnostics and monitoring.

• Continued revenue growth with lower cash burn: Record quarterly revenues alongside declining cash usage reinforce operating leverage and progress toward breakeven.

• PIMS integration unlocking utilisation: Integration into clinic workflows reduces friction, increasing test volumes and system usage across the installed base.

• Expansion of TRUFORMA assay menu: New assays across species increase product utility, encouraging repeat usage and strengthening recurring revenue.

• Achieving cash flow breakeven (~$55m revenue): Reaching this milestone removes a key investor overhang and demonstrates a self-sustaining model.

• AI-enabled ecosystem scaling: Data-driven diagnostics and monitoring create a compounding advantage and open new revenue opportunities over time.

Veterinary markets are inherently slow-moving and relationship-driven. Clinics require education, workflow changes, and clear economic justification before adopting new technologies. Zomedica’s products often introduce entirely new categories, such as AI-driven diagnostics or contactless monitoring, meaning adoption depends not just on product quality but on changing long-established behaviours. This creates a lag between product launch and meaningful revenue contribution. Even when initial placements occur, utilisation can take time to ramp as clinicians become comfortable incorporating the technology into daily practice. As a result, revenue growth may be more gradual than expected, particularly in early market penetration phases.

Zomedica has successfully built a broad and differentiated product portfolio through acquisitions and internal development. However, the next phase of value creation depends heavily on execution. This includes scaling the salesforce, driving adoption across multiple products, increasing utilisation within clinics, and maintaining operational discipline. There is also complexity in managing a multi-product ecosystem. Each product has its own sales cycle, training requirements, and value proposition. Ensuring that these products are effectively cross-sold and integrated into a cohesive offering is critical. Any breakdown in execution, whether in sales, marketing, or operations, could slow growth and delay the path to profitability.

The animal health market includes several large, well-capitalised incumbents alongside established traditional solutions. Competitors such as major diagnostic providers and pharmaceutical companies have deep customer relationships, extensive distribution networks, and significant pricing power. While Zomedica’s products are differentiated, particularly in areas like AI diagnostics and integrated workflows, competitors can respond over time. This may include launching competing products, bundling services, or using pricing strategies to defend market share. Additionally, some existing alternatives, such as reference labs, are deeply embedded in clinical workflows, making displacement challenging. Sustaining competitive advantage will depend on continued innovation, strong execution, and the ability to demonstrate clear clinical and economic value to veterinary practices.